Fort D, Mathis M, Fort C, Fort T, Guiney P, Weeks J. Polybrominated Diphenylether (DE-71) Exposure Skews Phenotypic Sex Ratio, and Alters Steroid Hormone Levels and Steroidogenic Enzyme Activities in Juvenile Silurana tropicalis. Toxicol Sci. 2019;: pubmed publisher

Jeon W, Kim O, Seo C, Jin S, Kim J, Shin H, et al. Inhibitory effects of Ponciri Fructus on testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Altern Med. 2017;17:384 pubmed publisher

Gentile P, Garcovich S, Bielli A, Scioli M, Orlandi A, Cervelli V. The Effect of Platelet-Rich Plasma in Hair Regrowth: A Randomized Placebo-Controlled Trial. Stem Cells Transl Med. 2015;4:1317-23 pubmed publisher

Montico F, Kido L, San Martin R, Rowley D, Cagnon V. Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences. Prostate. 2015;75:1643-61 pubmed publisher

Baek I, Ha E, Yoo J, Jung Y, Kim M. Design of a gelatin microparticle-containing self-microemulsifying formulation for enhanced oral bioavailability of dutasteride. Drug Des Devel Ther. 2015;9:3231-8 pubmed publisher

Chung K, An H, Cheon S, Kwon K, Lee K. Bee venom suppresses testosterone-induced benign prostatic hyperplasia by regulating the inflammatory response and apoptosis. Exp Biol Med (Maywood). 2015;240:1656-63 pubmed publisher

Kim M, Ha E, Choo G, Baek I. Preparation and in vivo evaluation of a dutasteride-loaded solid-supersaturatable self-microemulsifying drug delivery system. Int J Mol Sci. 2015;16:10821-33 pubmed publisher

Chau C, Price D, Till C, Goodman P, Chen X, Leach R, et al. Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PLoS ONE. 2015;10:e0126672 pubmed publisher

Yoshitake T, Takeda A, Ohki K, Inoue Y, Yamawaki T, Otsuka S, et al. Five-year efficacy of finasteride in 801 Japanese men with androgenetic alopecia. J Dermatol. 2015;42:735-8 pubmed publisher

Zhong X, Lin J, Zhou J, Xu W, Hong Z. Anti-proliferative effects of qianliening capsules on prostatic hyperplasia in vitro and in vivo. Mol Med Rep. 2015;12:1699-708 pubmed publisher

Said M, Hassan N, Schlicht M, Bosland M. Flaxseed suppressed prostatic epithelial proliferation in a rat model of benign prostatic hyperplasia. J Toxicol Environ Health A. 2015;78:453-65 pubmed publisher

Zwadlo C, Schmidtmann E, Szaroszyk M, Kattih B, Froese N, Hinz H, et al. Antiandrogenic therapy with finasteride attenuates cardiac hypertrophy and left ventricular dysfunction. Circulation. 2015;131:1071-81 pubmed publisher

Masrudin S, Mohamad J. Preventive effect of Pueraria mirifica on testosterone-induced prostatic hyperplasia in Sprague Dawley rats. Andrologia. 2015;47:1153-9 pubmed publisher

Montico F, Kido L, Hetzl A, Cagnon V. Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. Prostate. 2015;75:484-99 pubmed publisher

Chu N, Xu H, Wang G, Wang J, Chen W, Yuan F, et al. Pharmacokinetic interaction of finasteride with tamsulosin hydrochloride: an open-label, randomized, 3-period crossover study in healthy Chinese male volunteers. Clin Ther. 2015;37:462-72 pubmed publisher

Lee S, Park J, Kim D, Bae S, Chin Y, Oh E, et al. In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug-drug interactions. Toxicol Lett. 2015;232:458-65 pubmed publisher

Ishikawa M, Yoshitomi T, Zorumski C, Izumi Y. Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model. Invest Ophthalmol Vis Sci. 2014;55:8531-41 pubmed publisher

Lee R, Kim J, Chao D, Kuo L, Mally A, McClean M, et al. Progesterone and allopregnanolone improves stroke outcome in male mice via distinct mechanisms but neither promotes neurogenesis. J Neurochem. 2015;132:32-7 pubmed publisher

Zou Y, Sun Q, Li J, Yang C, Yang J, Zhang L. Effects of E/Z isomers of lycopene on experimental prostatic hyperplasia in mice. Fitoterapia. 2014;99:211-7 pubmed publisher

Yang X, Yuan L, Xiong C, Yin C, Ruan J. Abacopteris penangiana exerts testosterone-induced benign prostatic hyperplasia protective effect through regulating inflammatory responses, reducing oxidative stress and anti-proliferative. J Ethnopharmacol. 2014;157:105-13 pubmed publisher

Afriyie D, Asare G, Bugyei K, Adjei S, Lin J, Peng J, et al. Treatment of benign prostatic hyperplasia with Croton membranaceus in an experimental animal model. J Ethnopharmacol. 2014;157:90-8 pubmed publisher

Irwig M. Androgen levels and semen parameters among former users of finasteride with persistent sexual adverse effects. JAMA Dermatol. 2014;150:1361-3 pubmed publisher

Izumi Y, Zorumski C. Metaplastic effects of subanesthetic ketamine on CA1 hippocampal function. Neuropharmacology. 2014;86:273-81 pubmed publisher

Miao Y, Guo W, Shi W, Fang W, Liu Y, Liu J, et al. Midazolam ameliorates the behavior deficits of a rat posttraumatic stress disorder model through dual 18 kDa translocator protein and central benzodiazepine receptor and neurosteroidogenesis. PLoS ONE. 2014;9:e101450 pubmed publisher

Wissing M, Kluetz P, Ning Y, Bull J, Merenda C, Murgo A, et al. Under-representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993-2013. Cancer. 2014;120:3025-32 pubmed publisher

Zheng F, Rao Y, Lou Y, Lu X. A validated RP-HPLC method to investigate finasteride in human skin after in vitro topically applying vesicular nanocarrier. Pak J Pharm Sci. 2014;27:525-9 pubmed

Kido L, Hetzl A, Cândido E, Montico F, Lorencini R, Cagnon V. Antiangiogenic and finasteride therapies: responses of the prostate microenvironment in elderly mice. Life Sci. 2014;106:58-70 pubmed publisher

Bauman T, Sehgal P, Johnson K, Pier T, Bruskewitz R, Ricke W, et al. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues. Prostate. 2014;74:923-32 pubmed publisher

Santoru F, Berretti R, Locci A, Porcu P, Concas A. Decreased allopregnanolone induced by hormonal contraceptives is associated with a reduction in social behavior and sexual motivation in female rats. Psychopharmacology (Berl). 2014;231:3351-64 pubmed publisher

Liu X, Li W, Dai L, Zhang T, Xia W, Liu H, et al. Early repeated administration of progesterone improves the recovery of neuropathic pain and modulates spinal 18kDa-translocator protein (TSPO) expression. J Steroid Biochem Mol Biol. 2014;143:130-40 pubmed publisher

Ryu H, Kwon D. Reversible myopathy and ophthalmoparesis after low-dose finasteride administration for androgenic alopecia. Dermatol Surg. 2014;40:595-7 pubmed publisher

Bissegger S, Martyniuk C, Langlois V. Transcriptomic profiling in Silurana tropicalis testes exposed to finasteride. Gen Comp Endocrinol. 2014;203:137-45 pubmed publisher

Vano Galvan S, Molina Ruiz A, Serrano Falcón C, Arias Santiago S, Rodrigues Barata A, Garnacho Saucedo G, et al. Frontal fibrosing alopecia: a multicenter review of 355 patients. J Am Acad Dermatol. 2014;70:670-678 pubmed publisher

Rees J. Are 5-ARIs suitable for prevention of prostate cancer?. Practitioner. 2013;257:5 pubmed

Walsh P. Survival in the prostate cancer prevention trial. N Engl J Med. 2013;369:1967 pubmed publisher

Tangen C, Goodman P, Thompson I. Survival in the prostate cancer prevention trial. N Engl J Med. 2013;369:1968 pubmed publisher

Hotaling J. Finasteride and male infertility: a case for prospective collaborative research databases?. Fertil Steril. 2013;100:1528-9 pubmed publisher

Samplaski M, Lo K, Grober E, Jarvi K. Finasteride use in the male infertility population: effects on semen and hormone parameters. Fertil Steril. 2013;100:1542-6 pubmed publisher

Check J, Cohen R. Dihydrotestosterone may contribute to the development of migraine headaches. Clin Exp Obstet Gynecol. 2013;40:217-8 pubmed

Lefevre M. A role for finasteride in the prevention of prostate cancer?. N Engl J Med. 2013;369:670-1 pubmed publisher

Thompson I, Goodman P, Tangen C, Parnes H, Minasian L, Godley P, et al. Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med. 2013;369:603-10 pubmed publisher

Arena F. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia]. Minerva Urol Nefrol. 2013;65:211-6 pubmed

Stanczyk F. Response to commentary. J Steroid Biochem Mol Biol. 2013;138:463 pubmed publisher

Traish A, Morgentaler A. Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:462 pubmed publisher

Li M, Yang X, Wang H, Xu E, Xi Z. Inhibition of androgen induces autophagy in benign prostate epithelial cells. Int J Urol. 2014;21:195-9 pubmed publisher

Chhipa R, Halim D, Cheng J, Zhang H, Mohler J, Ip C, et al. The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. Prostate. 2013;73:1483-94 pubmed publisher

Wu Y, Godoy A, Azzouni F, Wilton J, Ip C, Mohler J. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. Prostate. 2013;73:1470-82 pubmed publisher

Kormos W. On call. I have read several news reports that claim finasteride, which I take for my prostate problem, can cause permanent impotence. Should I be concerned?. Harv Mens Health Watch. 2013;17:2 pubmed

Gupta A, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatolog Treat. 2014;25:156-61 pubmed publisher

Collier R. Propecia lawsuits: the lasting effects of delayed drug warnings. CMAJ. 2013;185:E455-6 pubmed publisher

Masoodi K, Ramos Garcia R, Pascal L, Wang Y, Ma H, O Malley K, et al. 5?-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology. 2013;154:2296-307 pubmed publisher

Bird S, Brophy J, Hartzema A, Delaney J, Etminan M. Male breast cancer and 5α-reductase inhibitors finasteride and dutasteride. J Urol. 2013;190:1811-4 pubmed publisher

Randhawa H, Hamilton J, Pope E. Finasteride for the treatment of hidradenitis suppurativa in children and adolescents. JAMA Dermatol. 2013;149:732-5 pubmed publisher

Thakre P, Tundulwar M, Chopde C, Ugale R. Neurosteroid allopregnanolone attenuates development of nicotine withdrawal behavior in mice. Neurosci Lett. 2013;541:144-9 pubmed publisher

Stanczyk F, Azen C, Pike M. Effect of finasteride on serum levels of androstenedione, testosterone and their 5?-reduced metabolites in men at risk for prostate cancer. J Steroid Biochem Mol Biol. 2013;138:10-6 pubmed publisher

Kim H, Chang H, Lee D. Simulative evaluation of taurine against alopecia caused by stress in Caenorhabditis elegans. Adv Exp Med Biol. 2013;776:267-76 pubmed publisher

Ricci G, Martinelli M, Luppi S, Lo Bello L, De Santis M, Skerk K, et al. Finasteride and fertility: case report and review of the literature. J Drugs Dermatol. 2012;11:1511-3 pubmed

Fwu C, Eggers P, Kaplan S, Kirkali Z, Lee J, Kusek J. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol. 2013;190:187-93 pubmed publisher

Murtola T, Kujala P, Tammela T. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. Prostate. 2013;73:923-31 pubmed publisher

Neuhouser M, Platz E, Till C, Tangen C, Goodman P, Kristal A, et al. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila). 2013;6:91-9 pubmed publisher

Rossi A, Mari E, Scarnò M, Garelli V, Maxia C, Scali E, et al. Comparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year study. Int J Immunopathol Pharmacol. 2012;25:1167-73 pubmed

Lin Y, Wang J, Jiang Y, Luo Y. [Factors influencing finasteride medication compliance in outpatients with benign prostatic hyperplasia]. Zhonghua Nan Ke Xue. 2012;18:891-5 pubmed

Ishihara Y, Kawami T, Ishida A, Yamazaki T. Allopregnanolone-mediated protective effects of progesterone on tributyltin-induced neuronal injury in rat hippocampal slices. J Steroid Biochem Mol Biol. 2013;135:1-6 pubmed publisher

Yousofvand N, Zarei F, Ghanbari A. Exogenous testosterone, finasteride and castration effects on testosterone, insulin, zinc and chromium in adult male rats. Iran Biomed J. 2013;17:49-53 pubmed

Rubio Gayosso I, Ramirez Sanchez I, Ita Islas I, Ortiz Vilchis P, Gutiérrez Salmeán G, Meaney A, et al. Testosterone metabolites mediate its effects on myocardial damage induced by ischemia/reperfusion in male Wistar rats. Steroids. 2013;78:362-9 pubmed publisher

Mòdol L, Darbra S, Vallée M, Pallares M. Alteration of neonatal Allopregnanolone levels affects exploration, anxiety, aversive learning and adult behavioural response to intrahippocampal neurosteroids. Behav Brain Res. 2013;241:96-104 pubmed publisher

Madheswaran T, Baskaran R, Thapa R, Rhyu J, Choi H, Kim J, et al. Design and in vitro evaluation of finasteride-loaded liquid crystalline nanoparticles for topical delivery. AAPS PharmSciTech. 2013;14:45-52 pubmed publisher

Rick F, Saadat S, Szalontay L, Block N, Kazzazi A, Djavan B, et al. Hormonal manipulation of benign prostatic hyperplasia. Curr Opin Urol. 2013;23:17-24 pubmed publisher

Tanglertsampan C. Efficacy and safety of 3% minoxidil versus combined 3% minoxidil / 0.1% finasteride in male pattern hair loss: a randomized, double-blind, comparative study. J Med Assoc Thai. 2012;95:1312-6 pubmed

Nepple K, Andriole G. Prostate cancer chemoprevention with 5α-reductase inhibitors. Urol Oncol. 2012;30:553-4 pubmed

Gur S, Kadowitz P, Hellstrom W. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation. Expert Opin Drug Saf. 2013;12:81-90 pubmed publisher

Banka N, Bunagan M, Shapiro J. Pattern hair loss in men: diagnosis and medical treatment. Dermatol Clin. 2013;31:129-40 pubmed publisher

Motofei I, Rowland D, Georgescu S, Baconi D, Dimcevici N, Paunica S, et al. A pilot study on the sexual side effects of finasteride as related to hand preference for men undergoing treatment of male pattern baldness. BJU Int. 2013;111:E221-6 pubmed publisher

Umar A, Dunn B, Greenwald P. Future directions in cancer prevention. Nat Rev Cancer. 2012;12:835-48 pubmed publisher

Boychenko O, Bernstein R, Schweiger E. Finasteride in the treatment of female pattern (androgenic) alopecia: a case report and review of the literature. Cutis. 2012;90:73-6 pubmed

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Berthold D, Lhermitte B, Uffer M, Doerfler A. Finasteride-related Leydig cell tumour: report of a case and literature review. Andrologia. 2012;44 Suppl 1:836-7 pubmed publisher

Atif F, Sayeed I, Yousuf S, Ishrat T, Hua F, Wang J, et al. Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence. Mol Med. 2011;17:1084-94 pubmed publisher

Shuang Z, Jiazhen W, Lijuan Y, Zhuo L, Dahai Y, Jinfeng L, et al. Synthesis and bioactivity of new Finasteride conjugate. Bioorg Med Chem Lett. 2011;21:3439-42 pubmed publisher

Thomas S, Yang X, Sampson N. Inhibition of the M. tuberculosis 3?-hydroxysteroid dehydrogenase by azasteroids. Bioorg Med Chem Lett. 2011;21:2216-9 pubmed publisher

Krome S. [How effective is finasteride?]. Dtsch Med Wochenschr. 2011;136:354 pubmed publisher

Hulin Curtis S, Petit D, Figg W, Hsing A, Reichardt J. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncol. 2010;6:1897-913 pubmed publisher

Yao Z, Xu Y, Zhang M, Jiang S, Nicklaus M, Liao C. Discovery of a novel hybrid from finasteride and epristeride as 5α-reductase inhibitor. Bioorg Med Chem Lett. 2011;21:475-8 pubmed publisher

Mella J, Perret M, Manzotti M, Catalano H, Guyatt G. Efficacy and safety of finasteride therapy for androgenetic alopecia: a systematic review. Arch Dermatol. 2010;146:1141-50 pubmed publisher

Tacklind J, Fink H, MacDonald R, Rutks I, Wilt T. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2010;:CD006015 pubmed publisher

Lynn R, Krunic A. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?. Dermatol Ther. 2010;23:544-6 pubmed publisher

Chaudhary U, Turner J. Finasteride. Expert Opin Drug Metab Toxicol. 2010;6:873-81 pubmed publisher

Stout S, Stumpf J. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010;44:1090-7 pubmed publisher

Dhingra N, Bhardwaj T, Mehta N, Mukhopadhyay T, Kumar A, Kumar M. Synthesis, antiproliferative, acute toxicity and assessment of antiandrogenic activities of some newly synthesized steroidal lactams. Eur J Med Chem. 2010;45:2229-36 pubmed publisher

Varma M, Obach R, Rotter C, Miller H, Chang G, Steyn S, et al. Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem. 2010;53:1098-108 pubmed publisher

Lebdai S, Bigot P, Azzouzi A. High-grade prostate cancer and finasteride. BJU Int. 2010;105:456-9 pubmed publisher

Aggarwal S, Thareja S, Bhardwaj T, Kumar M. 3D-QSAR studies on unsaturated 4-azasteroids as human 5alpha-reductase inhibitors: a self organizing molecular field analysis approach. Eur J Med Chem. 2010;45:476-81 pubmed publisher

Bellavance E, Luu The V, Poirier D. Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone. J Med Chem. 2009;52:7488-502 pubmed publisher

Yuan J, Johnson R, Huang R, Wichterman J, Jiang H, Hayton K, et al. Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum. Nat Chem Biol. 2009;5:765-71 pubmed publisher

Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila). 2009;2:518-24 pubmed publisher

Varma M, Feng B, Obach R, Troutman M, Chupka J, Miller H, et al. Physicochemical determinants of human renal clearance. J Med Chem. 2009;52:4844-52 pubmed publisher

Liu J, Shiono J, Shimizu K, Kukita A, Kukita T, Kondo R. Ganoderic acid DM: anti-androgenic osteoclastogenesis inhibitor. Bioorg Med Chem Lett. 2009;19:2154-7 pubmed publisher

De Nunzio C, Miano R, Trucchi A, Finazzi Agrò E, Tubaro A. Finasteride for prostatic disease: an updated and comprehensive review. Expert Opin Drug Metab Toxicol. 2008;4:1561-8 pubmed

Obach R, Lombardo F, Waters N. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab Dispos. 2008;36:1385-405 pubmed publisher

Bhardwa J, Goldstraw M, Tzortzis S, Kirby R. Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2007;8:1337-44 pubmed

Liu J, Shimizu K, Konishi F, Kumamoto S, Kondo R. The anti-androgen effect of ganoderol B isolated from the fruiting body of Ganoderma lucidum. Bioorg Med Chem. 2007;15:4966-72 pubmed

McCarthy A, Hartmann R, Abell A. Evaluation of 4'-substituted bicyclic pyridones as non-steroidal inhibitors of steroid 5alpha-reductase. Bioorg Med Chem Lett. 2007;17:3603-7 pubmed

D Amico A, Barry M. Prostate cancer prevention and finasteride. J Urol. 2006;176:2010-2; discussion 2012-3 pubmed

Norman B, Dodge J, Richardson T, Borromeo P, Lugar C, Jones S, et al. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia. J Med Chem. 2006;49:6155-7 pubmed

Fleshner N, Kulkarni G. Should finasteride be used to prevent prostate cancer?. Curr Treat Options Oncol. 2006;7:346-54 pubmed

Goetzl M, Holzbeierlein J. Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nat Clin Pract Urol. 2006;3:422-9 pubmed

Finn D, Beadles Bohling A, Beckley E, Ford M, Gililland K, Gorin Meyer R, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006;12:53-76 pubmed

Canby Hagino E, Brand T, Hernandez J, Thompson I. Chemoprevention of prostate cancer with finasteride. Expert Opin Pharmacother. 2006;7:899-905 pubmed

Molinie V, Ruffion A, Allory Y, Leroy X, Cochand Priollet B, Paraf F, et al. [Is tumour grade applicable to finasteride-treated prostate cancer?]. Prog Urol. 2005;15:387-91 pubmed

Handratta V, Vasaitis T, Njar V, Gediya L, Kataria R, Chopra P, et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem. 2005;48:2972-84 pubmed

Liang T, Cascieri M, Cheung A, Reynolds G, Rasmusson G. Species differences in prostatic steroid 5 alpha-reductases of rat, dog, and human. Endocrinology. 1985;117:571-9 pubmed